Small molecule drugs

JP2023548981A5Inactive Publication Date: 2024-11-13DIALECTIC THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023552161
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-10
Filing Date
2021-11-10
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Hydrophobic drug compounds face challenges in formulation due to insolubility in water-based solvents, necessitating the development of stable nanoemulsions that maintain biocompatibility and enhance drug delivery.

Method used

A nanoemulsion formulation of Compound 1 is developed, comprising a non-polar dispersoid in an aqueous medium, optimized with surfactants, osmotic agents, antioxidants, and pH regulators to achieve stable droplet sizes for effective drug delivery.

Benefits of technology

The formulation improves solubility, stability, and delivery of hydrophobic drugs, ensuring biocompatibility and maintaining desired droplet sizes for enhanced therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Disclosed are pharmaceutical nanoemulsion formulations, along with methods for making them, of Compound 1. An exemplary embodiment of a nanoemulsion of Compound 1 is composed of lecithin, medium-chain triglycerides (MCT), sucrose, EDTA, and water.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related Applications This application claims the benefit of U.S. Provisional Patent Application No. 63 / 112,132, filed November 10, 2020, which is incorporated herein by reference for all purposes.

[0002] The present invention relates to small molecule drug formulations and methods for their preparation and use. [Background technology]

[0003] In general, an emulsion is a dispersion of two immiscible liquids: one liquid forms the dispersed phase and the other liquid forms the dispersion medium, so that the dispersed phase is suspended in the dispersion medium in the form of droplets.

[0004] Generally, emulsions can be classified by the droplet size of the dispersed phase in the dispersion medium. Nanoemulsions are distinguished from macroemulsions by the emulsion droplet size. Nanoemulsions are emulsions in which the droplets are in the nanometer size range. Macroemulsions are emulsions with large droplet sizes. Typical droplet sizes for nanoemulsions can range from as small as 10 nm to as large as 200 nm or more. References herein to nanoemulsion droplet size refer to the average droplet size of the nanoemulsion.

[0005] Nanoemulsions have proven useful for drug delivery and formulation. Nanoemulsions are particularly useful for formulating drugs that are hydrophobic or have bioavailability or metabolic problems. Hydrophobic compounds are generally insoluble in aqueous formulations and other highly polar solvents. To ensure proper drug delivery, it is generally preferable for the drug component to be soluble in the formulation medium. Water or highly polar solvent-based formulations are also necessary to ensure the biocompatibility of the formulation. Because hydrophobic drug compounds are not easily soluble in water or other suitable biocompatible solvents, highly hydrophobic drug compounds present challenges in formulating them in suitable biocompatible solvents.

[0006] The use of nanoemulsion formulations is one approach to solving the formulation problems of hydrophobic drug compounds. Typically, drug compounds are dissolved in a solvent or vehicle in which they are soluble, but that solvent does not provide an ideal biocompatible solvent for the drug formulation. The resulting drug solution is mixed with a biocompatible solvent. The resulting mixture is stabilized with an emulsifier to produce droplets of the solvent used to dissolve the drug compound suspended in the biocompatible solvent. This allows the drug compound to be dissolved in the formulation while ensuring that the main solvent of the formulation is adequately biocompatible.

[0007] In general, nanoemulsions and emulsions can be classified as oil-in-water emulsions or water-in-oil emulsions. Oil-in-water emulsions have a lipophilic dispersoid, such as oil or a hydrophobic non-polar solvent, suspended in a hydrophilic dispersion medium, such as water or a highly polar solvent. Water-in-oil emulsions have a hydrophilic solvent, such as water, as the dispersoid and a hydrophobic solvent as the dispersion medium. Oil-in-water emulsions are preferred when used to formulate pharmaceutically active compounds. The hydrophobic dispersoid dissolves and disperses water-insoluble pharmaceutically active compounds, while the hydrophilic dispersion medium ensures the formulation's biocompatibility. Oil-in-water emulsions are more common in injectable formulations, where oil droplets ranging from 50 to 5000 nm are maintained suspended in the aqueous phase. For example, injectable emulsion formulations such as DIPROVAN® (propofol injection) and INTRALIPIDS® (intravenous fat emulsion) contain droplets with diameters of approximately 150-500 nm.

[0008] To successfully create a stable nanoemulsion, the formulation components must be carefully selected to suit the specific application and desired properties. While it may be possible to form a nanoemulsion using only a suitable dispersed phase and a suitable dispersion medium to dissolve the drug compound, this is not often the case. It is quite common to need to add multiple components to a drug formulation to enhance and promote proper nanoemulsion formation, formulation stability, and suitability for use as a drug delivery vehicle. Generally, these components include additives such as lipids, salts, oils, surfactants, cosolvents, salts, pH adjusters, buffers, etc. Many of these types of components are added to nanoemulsion formulations to promote the proper formation of a nanoemulsion between the dispersed phase and the dispersion medium.

[0009] The desired properties of a nanoemulsion formulation will vary depending on the particular intended application and use of the formulation. Target physical properties of nanoemulsion formulations that are often important include drug concentration, drug stability, nanoemulsion droplet size, pH, appearance, dilutability in biocompatible solvents and fluids, osmolality, zeta potential, filterability, viscosity, syringeability, and the physical stability of the nanoemulsion.

[0010] Therefore, developing a nanoemulsion formulation for a particular active pharmaceutical agent requires intensive research into the combination of dispersion medium, dispersoid, and excipients to achieve the desired result, including, but not limited to, consideration of the type and properties of the excipients, the physical and chemical properties of the active pharmaceutical agent, the chemical stability of the emulsion components, the physical stability of the emulsion, and the intended mode of drug delivery.

[0011] Nanoemulsions, which are highly dispersed emulsions in which nanometer-sized droplets are finely dispersed in a dispersion medium, offer advantages over typical macroemulsions. These advantages include a significant increase in surface area due to increased dispersion of the drug compound in the formulation; reduced turbidity; reduced viscosity; and a reduction in other undesirable physical formulation characteristics; and the ability to finely disperse the drug compound in a suitable biocompatible solvent. Furthermore, nanoemulsions are more thermodynamically and kinetically stable than macroemulsions. Once formed, the nanosized droplets of dispersoids in nanoemulsions are less likely to aggregate or agglomerate with each other compared to macroemulsions. Furthermore, nanoemulsions, due to their reduced droplet size, have a high interfacial area-to-volume ratio, which aids in the dissolution and distribution of poorly water-soluble pharmaceutically active compounds.

[0012] Nanoemulsions can be formed in a number of ways, including high-pressure homogenization, microfluidization, sonication, transitional phase inversion, catastrophic phase inversion, and self-nanoemulsification. Each of these methods, except for self-nanoemulsification, typically begins with the formation of a coarse emulsion. Subjecting the coarse emulsion to one of these processes reduces the emulsion droplet size into the nanometer range. Each of these methods is briefly described below.

[0013] High-pressure homogenization uses pressure forces to break down coarse emulsion droplets into nanometer-sized droplets. Generally, in this method, the coarse emulsion is forced through a constricted orifice or multiple constricted orifices using pressure. A combination of several forces, such as turbulence, hydraulic shear, and cavitation, acts on the coarse emulsion to produce droplets in the nanometer range.

[0014] In microfluidization, nanoemulsions are formed by forcing coarse emulsions to mix on a microscale. The coarse emulsion is forced through a series of micro-sized channels, which forces the emulsion components to interact on a micro-mixing scale. The formation of nanometer-sized droplets is further enhanced by the collision of multiple fluid streams through the microchannels. Shear, cavitation, and impact forces form nanoemulsions.

[0015] Ultrasonication also forms nanoemulsions by subjecting a coarse emulsion to high-intensity ultrasound, which forms droplets in the nanometer range primarily due to the cavitation and turbulence forces induced by the ultrasound.

[0016] Phase inversion nanoemulsion formation is a low-energy formation method compared to high-pressure homogenization, microfluidization, and sonication. Phase inversion nanoemulsion formation relies on the spontaneous change of surfactants in the formulation that occurs upon changes in parameters such as temperature and composition. There are many subtypes of phase inversion. In general, they all generate droplets in the nanometer range using spontaneous changes of surfactants that affect the emulsion droplet size.

[0017] Nanoemulsions can also be formed via self-emulsification, which occurs when the components of a formulation essentially form an emulsion with droplet sizes in the nanometer range. However, because drug formulations vary in desirable physical and chemical properties, it is relatively rare for suitable nanoemulsions with desirable properties to form via self-emulsification. Summary of the Invention

[0018] One aspect of the present invention relates to nanoemulsion formulations of Compound 1, in which Compound 1 is dissolved in a non-polar dispersoid suspended in droplet form in an aqueous or polar, water-miscible dispersion medium. The formulation can include formulation additives to improve the physical and chemical properties of the formulation; promote dissolution, distribution, and drug delivery of Compound 1; and optimize nanoemulsion properties, such as drug loading, droplet size, zeta potential, osmolality, pH, physical properties, and stability.

[0019] Another aspect of the present invention includes methods for making the nanoemulsion formulations of Compound 1 described. [Brief explanation of the drawings]

[0020] [Figure 1] FIG. 1 is a flow diagram illustrating one embodiment of a method for making a nanoemulsion formulation of Compound 1. DETAILED DESCRIPTION OF THE INVENTION

[0021] The following disclosure relates to nanoemulsion formulations and methods of forming nanoemulsion formulations of Compound 1 or pharmaceutically acceptable salts of Compound 1.

[0022] [ka] compound 1

[0023] In another aspect, the disclosure includes a method for forming a nanoemulsion formulation of Compound 1 or a nanoemulsion formulation of a pharmaceutically acceptable salt of Compound 1.

[0024] On the other hand, Compound 1 is an example of a small molecule with many polar functional groups. It is generally hydrophobic and not soluble enough in water or aqueous solvent mixtures to allow Compound 1 to be properly formulated for use in drug formulations. However, Compound 1 is sufficiently soluble in various polar organic solvents. However, these polar organic solvents are generally not pharmaceutically acceptable for use in drug formulations.

[0025] The nanoemulsion formulation of Compound 1 described below provides a pharmaceutically acceptable solution to the solubility problem of Compound 1.

[0026] In one embodiment, the nanoemulsion formulation of Compound 1 is composed of a dispersoid suspended in a dispersion medium. The dispersoid is a solvent capable of dissolving Compound 1. Non-limiting examples of such solvents include water-immiscible organic solvents; oils; glycerides; fats; lipophilic solvents; and mixtures of any two or more of these solvents. Non-limiting examples of dispersion mediums include water; water-miscible solvents; hydrophilic solvents; and mixtures of any two or more of these solvents.

[0027] Nanoemulsions of Compound 1 may contain other ingredients to improve the formulation or properties of the nanoemulsion. Examples of such other ingredients include surfactants, emulsifiers, osmolality adjusters, antioxidants / stabilizers, pH adjusters, inorganic salts, buffers, and combinations or mixtures thereof.

[0028] Oils for use in nanoemulsions include any one or more vegetable oils, non-limiting representative examples of which include castor oil, soybean oil, sesame oil, safflower oil, corn oil, palm oil, linseed oil, mineral oil, olive oil, and peanut oil. Glycerides that can be used in nanoemulsion formulations include monoglycerides, diglycerides, and triglycerides, each of which may be long-, medium-, or short-chain glycerides, or combinations thereof. As used herein, "long-chain triglycerides" refer to triesters of glycerol containing a mixture of saturated and unsaturated fatty acids with a carbon length of 18 to 24. Meanwhile, "medium-chain triglycerides" refer to triesters of glycerol with a carbon length of 6 to 12. "Short-chain triglycerides" are fatty acids containing chains of less than six carbons. In non-limiting examples, the oil concentration in nanoemulsion formulations ranges from 0.1% to 40% by weight. In another non-limiting example, the oil concentration in the nanoemulsion ranges from 5.0% to 30.0% by weight. In another non-limiting example, the oil concentration ranges from 10.0% to 25.0% by weight.

[0029] In another embodiment, the nanoemulsion of Compound 1 contains one or more surfactants, which reduce the interfacial tension and make the droplets in the dispersed phase more thermodynamically stable, reducing the tendency toward aggregation, creaming, and oil droplet growth. Such surfactants can be ionic or nonionic. Non-limiting examples of surfactants that can be incorporated into nanoemulsion formulations include lecithin, polyethylene glycol (PEG) lipids, Pluronic® F68, and sodium oleate. Lecithin is widely used to stabilize injectable nanoemulsions.

[0030] In a representative example of a nanoemulsion of Compound 1, lecithin is used as both a solubilizer and an emulsifier. Lecithin is a natural phospholipid that can be obtained from soybeans, eggs, sunflower seeds, etc. In a representative example of this embodiment, the lecithin is an injectable lecithin that is free of irritating, inflammatory, and immunogenic substances (examples of which are proteins). The lecithin contains more than 90% by weight of phosphatidylcholine (PC), such as Phospholipon 90G (PL90G). The lecithin or surfactant concentration in the nanoemulsion formulation can range from 0.1% to 40% by weight. In another example, the surfactant concentration in the nanoemulsion ranges from 5.0% to 30.0% by weight, or alternatively, from 10.0% to 25.0% by weight.

[0031] As used herein, an osmolality modifier is an agent used in a composition to increase the osmolality of a nanoemulsion of Compound 1. A nanoemulsion of Compound 1 according to any one of the above embodiments or examples has an osmolality in the range of 100 to 1000 mOsm, however, alternatively in the range of 200 to 400 mOsm, or 300 mOsm. Non-limiting representative examples of osmolality modifiers that can be introduced into a nanoemulsion formulation to increase osmolality include, but are not limited to, potassium chloride, sodium chloride, sugars, such as disaccharides (e.g., sucrose, mannitol, trehalose, etc.), glycerol, and mixtures of any two or more thereof. A preferred osmolality modifier for the nanoemulsion formulations described herein is sucrose, used in the range of 1% to 20% w / w.

[0032] Any of the embodiments of nanoemulsions of Compound 1 described herein may optionally include one or more antioxidants, stabilizers, or both to prevent or delay oxidation of the lipid components (e.g., lecithin and oil) in the nanoemulsion. Any pharmaceutically acceptable stabilizer or antioxidant can be used, non-limiting examples of which include inert gases, glucose, fructose, cysteine, L-methionine, and metal chelators such as ethylenediaminetetraacetic acid (EDTA). Each of the disclosed embodiments and examples of nanoemulsion formulations of Compound 1 may optionally include calcium disodium EDTA as an antioxidant, at a concentration ranging from 0.001 to 0.2% by weight, or alternatively, from 0.01 to 0.06% by weight.

[0033] pH adjusters may be added to the nanoemulsion to achieve the desired final pH. pH adjusters that can be added to the formulation include organic and inorganic acids and bases or their conjugate acids and bases. Suitable pH adjusters include, but are not limited to, lactic acid, acetic acid, citric acid, phosphoric acid, arginine, histidine, and glycine. Buffers can also be added to the nanoemulsion formulation to control the resulting pH of the formulation. Non-limiting examples of buffers that can be used include citric acid, lactic acid, acetic acid, histidine, phosphoric acid, and glycine-NaOH buffers. The pH of the nanoemulsion formulation can range from 3.0 to 10.0. The pH of the nanoemulsion formulation is more preferably in the range of 4.0 to 9.0, and even more preferably in the range of 4.0 to 8.0. Even more preferably, the pH of the nanoformulation is in the range of 4.0 to 7.0.

[0034] Nanoemulsion formulations of Compound 1 can be made by dissolving Compound 1 in a dispersoid; dissolving any additional lipophilic components in the dispersoid; dissolving any water-soluble or hydrophilic components in the dispersion medium; mixing the resulting coarse emulsions together; and, if necessary, treating the resulting coarse emulsion to form nano-sized emulsion droplets of the dispersoid in the dispersion medium.

[0035] The mixture obtained by mixing the dispersion medium liquid and the dispersoid liquid can produce a mixture, a macroemulsion, or a nanoemulsion. If a mixture or macroemulsion is obtained, further processing of the resulting mixture is then required to convert the resulting mixture into a suitable nanoformulation. This can be done by any suitable known nanoemulsification procedure, for example, by microfluidization, ultrasonication, high-pressure homogenization, or phase inversion. Any such method can be used to produce a nanoemulsion with a desired droplet size. Furthermore, the resulting mixture of dispersoid and dispersion medium can be processed multiple times by any one or combination of nanoemulsification methods to achieve the desired droplet size.

[0036] The droplet size of the dispersoid obtained in the dispersoid in the resulting nanoemulsion can be in the range of 10 to 500 nm, preferably in the range of 20 to 100 nm, and even more preferably in the range of 40 to 80 nm.

[0037] The weight ratio of dispersoid to dispersion medium can be in the range of 20:1 to 1:20. More preferably, the volume ratio of dispersoid to dispersion medium is in the range of 2:1 to 1:20, more preferably in the range of 2:1 to 1:5.

[0038] A representative embodiment of a nanoemulsion formulation can be formed as follows: 0.1-3.0% w / w of Compound 1 can be mixed or dissolved with 5.0-50.0% w / w of glycerides, e.g., long-chain triglycerides and medium-chain triglycerides, and oils, fats, or a mixture of the foregoing. If Compound 1 is not completely dissolved in the resulting mixture, a small amount of a polar, volatile organic solvent, e.g., methanol or ethanol, can be added to facilitate dissolution of Compound 1. Once Compound 1 is dissolved, the polar, volatile organic solvent can be removed by evaporation. 0.1-30.0% w / w of one or more surfactants or emulsifiers, e.g., sucrose, is then added to the resulting solution and thoroughly mixed. 50.0-80.0% w / w of water is then added and thoroughly mixed to form a mixture, macroemulsion, or microemulsion. The resulting product is then processed by any known method of nanoemulsion formation, such as high shear and microfluidization, until a nanoemulsion with the appropriate droplet size is formed.

[0039] Reference is now made to FIG. 1 , which illustrates one embodiment of a method for preparing a nanoemulsion formulation of Compound 1. The nanoemulsion was produced using an emulsification solvent evaporation method. This method uses a volatile solvent (e.g., ethanol, chloroform, ethyl acetate, and dichloromethane) evaporated at high temperature, under vacuum, or by continuous stirring to solubilize the lipid components, and then emulsify the resulting lipid film with an aqueous phase. Ethanol is the most pharmaceutically acceptable organic and volatile solvent. In step 110, preparation of the lipid phase components of the nanoemulsion begins by combining medium-chain triglycerides (MCTs), lecithin, the active pharmaceutical ingredient (API), and ethanol. In step 112, the solution resulting from step 110 is subjected to rotary evaporation to remove ethanol to 2% by weight or less, which can be determined by mass comparison. In the embodiment of FIG. 1 , the resulting product is a lipid film containing the active pharmaceutical ingredient. The aqueous phase of the nanoemulsion is prepared in step 114, in which sucrose, EDTA, and water for injection are combined to produce an aqueous solution. In step 116, preparation of the nanoemulsion formulation begins by combining the lipid film from step 112 with the aqueous solution produced from step 114. The mixture from step 116 is subjected to high shear to form a homogenous mixture or emulsion and further disperse the lipid phase in the aqueous phase. In step 120, the pH of the resulting emulsion is adjusted using a suitable pH adjuster (i.e., 5N sodium hydroxide). Preferably, the resulting pH is in the range of 4.5 to 5.0, and more preferably, the resulting pH of the mixture is in the range of 4.8 to 5.0. In step 122, the pH-adjusted emulsion from step 120 is further subjected to high shear to reduce the emulsion droplet size and improve the nanoemulsion characteristics. The high shear treatment of step 120 is continued until the emulsion droplet size is preferably in the range of 300 to 500 nm. The emulsion resulting from step 124 is subjected to microfluidization to further reduce the emulsion droplet size. Preferably, microfluidization is carried out using a Y-chamber at 20,000-25,000 Psi at 10-15° C. Microfluidization is continued until the emulsion droplet size is reduced to the desired size.Preferably, microfluidization continues until the droplet size is reduced to the range of 50 to 150 nm.

[0040] Several exemplary formulations were prepared. In the following examples, the therapeutic agent is Compound 1. LCT is a USP-grade long-chain triglyceride, e.g., available from CRODA [Super refined soybean oil, SR49571, CRODA, NJ, USA]. MCT is a USP-grade medium-chain triglyceride, or miglyol 812, e.g., available from IOI Oleochemical [Witten, Germany]. Phospholipon 90G (PL90G) is an injection-grade lecithin, e.g., available from LIPOID [Newark, NJ, USA]. SWFI is a USP-grade sterile water for injection, e.g., available from OmniPur [Cat. No. 4.86505, Millipore Sigma, Burlington, Massachusetts, USA]. The sucrose used in the following formulation examples was a USP-grade sucrose, e.g., available from Spectrum. The Capsul MCM used was from Abitec. The Poloxamer 188 / F68 used was from BASF. [Example]

[0041] [Example 1] A 40 g batch of therapeutic agent nanoemulsion formulation was formed from the following ingredients: 0.2 g therapeutic agent, 4 g LCT, 4 g MCT, 4 g PL90G, 8 g sucrose, and 19.8 g SWFI. The LCT, MCT, PL90G, and therapeutic agent were added to a 100 mL round-bottom flask. The mixture was stirred until dissolved, resulting in a clear solution. If the mixture remained cloudy during mixing, sufficient ethanol was added until the mixture turned into a clear solution. If ethanol addition was required, the ethanol was removed from the mixture by rotavapor evaporation. Ethanol removal continued until residual ethanol was reduced to 2.0% or less by rotary evaporation, which could be confirmed by weight comparison. Removal of the ethanol resulted in a clear, transparent lipid phase. At this point, a separately prepared sucrose solution in SWFI was added to reconstitute the lipid phase. The remaining SWFI was then added to bring the total formulation weight to 40 g. The resulting formulation was subjected to high shear to reduce the droplet size to less than 500 nanometers. The resulting formulation was then microfluidized for five passes to reduce the droplet size to less than 100 nanometers. The resulting formulation had the following component percentages (% w / v): therapeutic agent 0.5%, LCT 10%, MCT 10%, PL90G 10%, sucrose 20%, SWFI 49.5%.

[0042] [Example 2] Another exemplary embodiment of a 40 g batch of nanoemulsion formulation was prepared as follows: 2 g of LCT, 2 g of MCT, 4 g of PL90G, and 0.2 g of therapeutic agent were added to a 100 mL round-bottom flask. The mixture was stirred until dissolved, resulting in a clear solution. If the mixture remained cloudy during mixing, sufficient ethanol was added until the mixture turned into a clear solution. If ethanol addition was required, the ethanol was removed from the mixture by rotavapor evaporation. Ethanol removal continued until the residual ethanol was reduced to 2.0% or less by rotary evaporation, which could be confirmed by weight comparison. Removal of the ethanol resulted in a clear lipid phase. A sucrose solution in SWFI was separately prepared using 8 g of sucrose and then added to reconstitute the lipid phase. The remaining SWFI was added to bring the total weight of the formulation to 40 g. The resulting formulation was subjected to high shear to reduce the droplet size to less than 500 nanometers. The resulting formulation was then microfluidized for five passes to yield droplets less than 100 nanometers in size. The resulting formulation had the following component percentages (% w / v): therapeutic agent 0.5%, LCT 5%, MCT 5%, PL90G 10%, sucrose 20%, SWFI 59.5%.

[0043] [Example 3] Another exemplary embodiment formulation was prepared as follows: 4 g of MCT, 4 g of PL90G, and 0.2 g of therapeutic agent were added to a 100 mL round-bottom flask. The mixture was stirred until dissolved, resulting in a clear solution. If the mixture remained cloudy during mixing, sufficient ethanol was added until the mixture turned into a clear solution. If ethanol addition was required, the ethanol was removed from the mixture by rotavapor evaporation. Ethanol removal continued until the residual ethanol was reduced to 2.0% or less by rotary evaporation, which could be confirmed by weight comparison. Removal of ethanol resulted in a clear lipid phase. A sucrose solution in SWFI was separately prepared using 8 g of sucrose and then added to reconstitute the lipid phase. The remaining SWFI was added to bring the total weight of the formulation to 40 g. The resulting formulation was subjected to high shear to reduce the droplet size to less than 500 nanometers. The resulting formulation was then microfluidized for five passes to reduce the droplet size to less than 100 nanometers. The resulting formulation had the following ingredient percentages (% w / v): therapeutic agent 0.5%, MCT 10%, PL90G 10%, sucrose 20%, and SWFI 59.5%.

[0044] The resulting formulations of Examples 1-3 were tested for pH, clarity, droplet size, zeta potential, assay, impurities, and dilutability in WFI or NS. The results are summarized in Table 1.

[0045] [Table 1]

[0046] [Example 4] Another exemplary embodiment formulation was prepared as follows: 2 g of LCT, 2 g of Capmul MCM, 4 g of PL90G, and 0.2 g of therapeutic agent were added to a 100 mL round-bottom flask. The mixture was stirred until dissolved, resulting in a clear solution. If the mixture remained cloudy during mixing, a sufficient amount of ethanol was added until the mixture turned into a clear solution. If ethanol addition was required, it was removed from the mixture by rotavapor evaporation. Complete removal of ethanol can be confirmed by weight comparison. Removal of ethanol resulted in a clear lipid phase. A sucrose solution in SWFI was separately prepared using 8 g of sucrose and then added to reconstitute the lipid phase. The remaining SWFI was added to bring the total weight of the formulation to 40 g. The resulting formulation was subjected to high shear to reduce the droplet size to less than 500 nanometers. The resulting formulation was then microfluidized for five passes to reduce the droplet size to less than 100 nanometers. The resulting formulation had the following ingredient percentages (% w / v): therapeutic agent 0.5%, LCT 5%, Capmul MCM 5%, PL90G 10%, sucrose 20%, SWFI 59.5%.

[0047] [Example 5] Another exemplary embodiment formulation was prepared as follows: 2 g of LCT, 2 g of MCT, 4 g of PL90G, and 0.6 g of therapeutic agent were added to a 100 mL round-bottom flask. The mixture was stirred until dissolved, resulting in a clear solution. If the mixture remained cloudy during mixing, a sufficient amount of ethanol was added until the mixture turned into a clear solution. If ethanol addition was required, it was removed from the mixture by rotavapor evaporation. Complete removal of ethanol can be confirmed by weight comparison. Removal of ethanol resulted in a clear lipid phase. A sucrose solution in SWFI was separately prepared using 8 g of sucrose, and this solution was then added to reconstitute the lipid phase. The remaining SWFI was added to bring the total weight of the formulation to 40 g. The resulting formulation was subjected to high shear to reduce the droplet size to less than 500 nanometers. The resulting formulation was then microfluidized five times to reduce the droplet size to less than 100 nanometers. The resulting formulation had the following ingredient percentages (% w / v): therapeutic agent 1.5%, LCT 5%, MCT 5%, PL90G 10%, sucrose 20%, SWFI 59.5%.

[0048] The resulting formulation of Example 5 had the properties listed in Table 2.

[0049] [Table 2]

[0050] [Example 6] Another exemplary embodiment formulation was prepared as follows: 1.6 g of MCT, 1.6 g of PL90G, and 0.2 g of therapeutic agent were added to a 100 mL round-bottom flask. The mixture was stirred until dissolved, resulting in a clear solution. If the mixture remained cloudy during mixing, a sufficient amount of ethanol was added until the mixture turned into a clear solution. If the addition of ethanol was necessary, the ethanol was removed from the mixture by rotavapor evaporation. Complete removal of ethanol can be confirmed by weight comparison. Removal of ethanol resulted in a clear lipid phase. Next, 3.6 g of sucrose dissolved in SWFI was added to reconstitute the lipid phase. SWFI was added to bring the total weight of the formulation to 20 g. The resulting formulation was subjected to high shear to reduce the droplet size to less than 500 nanometers. The resulting formulation was then microfluidized for five passes to reduce the droplet size to less than 100 nanometers. The resulting formulation had the following ingredient percentages (% w / v): therapeutic agent 1.0%, MCT 8%, PL90G 8%, sucrose 18%, SWFI 65%.

[0051] The resulting formulation of Example 6 had the properties listed in Table 3.

[0052] [Table 3]

[0053] [Example 7] Another exemplary embodiment formulation was prepared as follows: 1.6 g of MCT, 1.6 g of PL90G, and 0.2 g of therapeutic agent were added to a 100 mL round-bottom flask. The mixture was stirred until dissolved, resulting in a clear solution. If the mixture remained cloudy during mixing, a sufficient amount of ethanol was added until the mixture turned into a clear solution. If ethanol addition was required, the ethanol was removed from the mixture by rotavapor evaporation. Complete removal of ethanol can be confirmed by weight comparison. Removal of ethanol resulted in a clear lipid phase. Next, 2.4 g of sucrose in SWFI was added to reconstitute the lipid phase. SWFI was added to bring the total weight of the formulation to 20 g. The resulting formulation was subjected to high shear to reduce the droplet size to less than 500 nanometers. The resulting formulation was then microfluidized for five passes to reduce the droplet size to less than 100 nanometers. The resulting formulation had the following ingredient percentages (% w / v): therapeutic agent 1.0%, MCT 8%, PL90G 8%, sucrose 12%, SWFI 71%.

[0054] The resulting formulation of Example 6 had the properties listed in Table 4.

[0055] [Table 4]

[0056] [Example 8] Another exemplary embodiment formulation was prepared as follows: 1.6 g of MCT, 0.32 g of Poloxamer 188, 1.28 g of PL90G, and 0.2 g of therapeutic agent were added to a 100 mL round-bottom flask. The mixture was stirred until dissolved, resulting in a clear solution. If the mixture remained cloudy during mixing, a sufficient amount of ethanol was added until the mixture turned into a clear solution. If ethanol addition was required, the ethanol was removed from the mixture by rotavapor evaporation. Complete removal of ethanol can be confirmed by weight comparison. Removal of ethanol resulted in a clear lipid phase. Next, 1.6 g of sucrose in SWFI was added to reconstitute the lipid phase. SWFI was added to bring the total weight of the formulation to 20 g. The resulting formulation was subjected to high shear to reduce the droplet size to less than 500 nanometers. The resulting formulation was then microfluidized for five passes to reduce the droplet size to less than 100 nanometers. The resulting formulation had the following ingredient percentages (% w / v): therapeutic agent 1.0%, MCT 8%, PL90G 8%, sucrose 12%, SWFI 71%.

[0057] The resulting formulation of Example 6 had the properties listed in Table 5.

[0058] [Table 5]

[0059] [Examples 9-15] Exemplary formulations 9-15 were prepared as follows using the ingredients listed in Table 6. MCT, PL90G, and the therapeutic agent (Figure 1) were added to a 100 mL round-bottom flask and mixed until dissolved. If mixing these ingredients resulted in a non-clear suspension, ethanol was added until all ingredients were dissolved and the solution was clear. If ethanol was added, it was removed by rotary evaporation to form a clear liquid phase. Poloxamer 188 or sucrose in SWFI with or without glycerin was added to reconstitute the lipid phase. The resulting formulation was further diluted with SWFI to a total weight of 20 grams. The resulting formulation was subjected to high shear to reduce the droplet size to less than 500 nm. The resulting formulation was microfluidized five times to reduce the droplet size to less than 100 nm.

[0060] [Table 6]

[0061] The resulting formulations of Examples 9-15 had the properties listed in Table 7.

[0062] [Table 7]

[0063] The physical and chemical stability of Compound 1 was tested in nanoemulsion formulations. Batches of nanoemulsion were prepared at 5 mg / mL and 7.5 mg / mL of Compound 1 using the ingredients listed in Table 8 and designated Batch A and Batch B, respectively.

[0064] [Table 8]

[0065] The resulting nanoemulsion was sterilized through a 0.2 micron sterile filter, filled into glass vials (2 mL / vial), and crimp-sealed. The sealed vials were stored at -20°C, 2-8°C, and 25°C. Individual vials were withdrawn at 0 days, 2 weeks, 1 month, 3 months, and 6 months and tested for appearance, pH, clarity, particulate matter, assay, and Compound 1 impurities. The stability results are summarized in Table 9 below.

[0066] [Table 9]

[0067] Stability results showed that the nanoemulsion formulation of Compound 1 described herein was chemically stable over a period of six months.

[0068] [Examples 16 and 17] Two additional examples of nanoemulsion formulations according to the above procedure using the ingredients shown in Table 10

[0069] [Table 10]

[0070] While the present invention has been described with reference to specific embodiments, these descriptions are not intended to be construed in a limiting sense. Various modifications of the disclosed embodiments, as well as alternative embodiments of the invention, will be apparent to those skilled in the art upon reference to the description of the invention. Those skilled in the art will appreciate that the conception and specific embodiments disclosed may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present invention. Those skilled in the art will also realize that such equivalent constructions do not depart from the spirit and scope of the invention as set forth in the appended claims. It is therefore intended that the claims cover all such modifications or embodiments that fall within the true scope of the invention.

Claims

1. Compound 1 having the following molecular structure or a pharma- ceutically acceptable salt of Compound 1: [Formula 1] Dispersoids; and dispersion medium 13. A formulation comprising:

2. The formulation of claim 1 which is an emulsion.

3. The formulation of claim 2 which is a nanoemulsion.

4. 4. The formulation of any one of claims 1 to 3, further comprising one or more of a surfactant, an emulsifier; an osmolality adjusting agent, an antioxidant, a stabilizer, a pH adjusting agent, an inorganic salt, or a buffering agent.

5. 5. The formulation of claim 4, wherein the surfactant is lecithin, a polyethylene glycol (PEG) lipid, Pluronic® F68, or sodium oleate.

6. 5. The formulation of claim 4, wherein the osmolality adjusting agent is potassium chloride, sodium chloride, sugar, or glycerol.

7. 5. The formulation of claim 4, wherein the antioxidant is an inert gas, glucose, fructose, cysteine, L-methionine, a metal chelator, ethylenediaminetetraacetic acid (EDTA), or calcium disodium ethylenediaminetetraacetate.

8. 5. The formulation of claim 4, wherein the pH adjuster is lactic acid, acetic acid, citric acid, phosphoric acid, arginine, histidine, glycine, or a buffer.

9. 9. The formulation of any one of claims 1 to 8, wherein the dispersoid is a water-miscible organic solvent, an oil, a glyceride, a fat, a lipophilic solvent, or a mixture of two or more of a water-miscible organic solvent, an oil, a glyceride, a fat and a lipophilic solvent.

10. The formulation of any one of claims 1 to 9, wherein the dispersion medium is water, a water-miscible solvent, a hydrophilic solvent, or a mixture of two or more of water, a water-miscible solvent and a hydrophilic solvent.

11. The formulation of any one of claims 1 to 10, wherein the dispersoid is a long chain triglyceride, a medium chain triglyceride, or a short chain triglyceride.

12. 0.5-2.0% w / v of Compound 1; 0-10% w / v long chain triglycerides; 0-10% w / v medium chain triglycerides; 5-10% w / v lecithin; and 5-20% w / v sugar The formulation according to any one of claims 1 to 11, comprising:

13. 0.5% w / v Compound 1; 10% w / v long chain triglycerides; 10% w / v medium chain triglycerides; 10% w / v PL90G; and 20% w / v sucrose The formulation of claim 12, comprising:

14. 0.7% w / w of Compound 1; 8% w / w of medium chain triglycerides; 8% w / w PL90G; 18% w / w sucrose; and 0.6% w / w Na EDTA 2 H 2 O The formulation of claim 12, comprising:

15. 0.5-1.0% w / w of Compound 1; 5-10% w / w of medium chain triglycerides; 5-10% w / w PL90G; 10-20% w / w sucrose; and 0.01-2.0% w / w of Na EDTA 2 H 2 O The formulation of claim 12, comprising: